Saltar al contenido
Merck
Todas las fotos(2)

Documentos clave

Ver Toda la documentación

APOMAG-62K

Millipore

MILLIPLEX® Human Apolipoprotein Magnetic Bead Panel - Cardiovascular Disease Multiplex Assay

This Bead-Based Multiplex Assay, using the Luminex® xMAP® technology, enables the simultaneous analysis of Apo AI, Apo AII, Apo B, Apo CII, Apo CIII, Apo E.

Sinónimos:

human apolipoprotein CVD immunoassay panel, luminex human apolipoprotein cardiovascular disease multiplex assay, millipore human apolipoprotein CVD multiplex kit

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Código UNSPSC:
12161503
eCl@ss:
32161000
NACRES:
NA.84
To order a Milliplex® kit, please search for your analyte of interest.
Design And Price Your Kit

Características

This Bead-Based Multiplex Assay, using the Luminex® xMAP® technology, enables the simultaneous analysis of Apo AI, Apo AII, Apo B, Apo CII, Apo CIII, Apo E.

Nivel de calidad

200

reactividad de especies

human

fabricante / nombre comercial

Milliplex®

assay range

accuracy: 85%
(Apo E)
accuracy: 86%
(Apo AI)
accuracy: 89%
(Apo CIII)
accuracy: 92%
(Apo B)
sensitivity: 1.00 ng/mL
(Apo AII)
sensitivity: 1.22 ng/mL
(Apo CII)
sensitivity: 1.42 ng/mL
(Apo E)
sensitivity: 1.48 ng/mL
(Apo AI)
sensitivity: 1.71 ng/mL
(Apo CIII)
sensitivity: 4.84 ng/mL
(Apo B)

técnicas

multiplexing: suitable

método de detección

fluorometric (Luminex xMAP)

Condiciones de envío

wet ice

Categorías relacionadas

Descripción general

Metabolic Syndrome has received increased attention from the medical community with increasing cases of obesity, type 2 diabetes and related cardiovascular diseases being described and studied.

MILLIPLEX® Human Apolipoprotein Panel is a 6-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma, tissue culture supernatant or other biological samples: APOA-1, APOA-2, APOB, APOC-2, APOC-3, and APOE. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cardiovascular

Especificidad

Cross Reactivty
To test cross-reactivity among the assays in the panel, individual apolipoprotein standard was prepared at a concentration 4 times greater than the highest concentration in the calibration curve and tested in the 6-plex assays with multiplexed beads containing immobilized capture antibodies and individual detection antibodies. There was negligible cross-reactivity within the panel.

Aplicación

  • Analytes: Apo AI, Apo AII, Apo B, Apo CII, Apo CIII, Apo E
  • Recommended Sample Type: Human serum, plasma, tissue culture supernatant or other biological samples
  • Recommended Sample Dilution: 10 μL of a 1: 4,000 dilution of plasma or serum
  • Assay Run Time: Primary incubation of 1 hour followed by a secondary incubation of 30 minutes, both at room temperature (20-25°C)
  • Research Subcategory: Cardiovascular Disease

Características y beneficios

Design your multiplex kit by choosing available analytes within this panel.

Otras notas

Please contact Technical Service for linearity of dilution.
Standard curve range: Refer to the kit protocol for details.

Información legal

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Órganos de actuación

Respiratory Tract

Código de clase de almacenamiento

10 - Combustible liquids

Clase de riesgo para el agua (WGK)

WGK 3

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Consumption of buckwheat modulates the post-prandial response of selected gastrointestinal satiety hormones in individuals with type 2 diabetes mellitus.
Stringer, DM; Taylor, CG; Appah, P; Blewett, H; Zahradka, P
Metabolism, Clinical and Experimental null
Elise Grytten et al.
Clinical nutrition (Edinburgh, Scotland), 40(5), 2556-2575 (2021-05-03)
Marine-derived omega-3 (n-3) polyunsaturated fatty acids (PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower circulating levels of triacylglycerols (TAGs), and the plant-derived omega-6 (n-6) PUFA linoleic acid (LA) may reduce cholesterol levels. Clinical studies on effects of these
Xiaoke Yin et al.
Circulation. Cardiovascular genetics, 10(6) (2017-12-15)
Mass spectrometry is selective and sensitive, permitting routine quantification of multiple plasma proteins. However, commonly used nanoflow liquid chromatography (LC) approaches hamper sample throughput, reproducibility, and robustness. For this reason, most publications using plasma proteomics to date are small in
Yi-Ting Chen et al.
Molecular & cellular proteomics : MCP, 16(5), 799-811 (2017-02-27)
Multiple (selected) reaction monitoring (MRM/SRM) of peptides is a growing technology for target protein quantification because it is more robust, precise, accurate, high-throughput, and multiplex-capable than antibody-based techniques. The technique has been applied clinically to the large-scale quantification of multiple
Anastasiia S Boiko et al.
Heliyon, 5(7), e02033-e02033 (2019-07-19)
Schizophrenia is associated with a lowered life expectancy due to cardiovascular disease. This is, at least in part, related to an increased vulnerability to the development of metabolic syndrome (MetS) in patients with schizophrenia. The dysregulation of apolipoproteins (Apos) may
Ver todos los artículos relacionados

Contenido relacionado

Multiplex Measurement of CVD Biomarkers | MILLIPLEX® Assays

Learn about biomarkers of cardiovascular disease (CVD) and discover how multiplex CVD panels, such as MILLIPLEX® multiplex assays, are being used to increase the efficiency of biomarker discovery for CVD research.

Tips & Tricks | Guide to Multiplexing | MILLIPLEX® Assays

Uncover tips and tricks to multiplexing in this guide from the experts. Learn how you can enhance the power of your research with MILLIPLEX® multiplexing, including industry guidance for immunoassays, multiplexing tips, one-day MILLIPLEX® multiplex assays for limited lab time, and more.

Multiplexing Metabolic Syndrome Biomarkers | MILLIPLEX® Assays

Multiplex immunoassays, such as MILLIPLEX® multiplex metabolic assays, are critical in metabolic syndrome research because they provide a full picture of the different conditions related to it, like diabetes and obesity, as well as save time and sample volume.

Preguntas

  1. Can you provide information on whether Milliplex Human Apolipoprotein Magnetic Bead Panel kit measures a specific type of apolipoprotein proteoform or if it includes measurements for all types of proteoforms? (Cat# APOMAG-62K)

    1 respuesta

    1. The Milliplex Human Apolipoprotein Magnetic Bead Panel includes the following components:

      - APO AI: It consists of a capture antibody (monoclonal) designed against purified full length human apolipoprotein A1, and a detection antibody (monoclonal) specific to human APO A I, whether purified or in the form of HDL.

      - APO AII: This includes a capture antibody (polyclonal) specific for human apolipoprotein A II, and a detection antibody (polyclonal) also specific to human APO II.

      - APO B: It comprises a capture antibody (monoclonal) specific for native human APO B in the form of LDL, and a detection antibody (monoclonal) specific to human APO B in the form of LDL.

      - APO C II: This involves a capture antibody (polyclonal) specific to human APO CII, with a corresponding detection antibody (polyclonal) specific to human APO C II.

      - APO C III: It contains a capture antibody (polyclonal) specific to human APO CIII, along with a detection antibody (polyclonal) specific to human APO C III.

      - APO E: This component includes a capture antibody (polyclonal) specific to human APO E, and a detection antibody (polyclonal) specific to human APO E.

      ¿Le ha resultado útil?

Revisiones

Sin puntuación

Filtros activos

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico